A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Trial Profile

A Phase 1b, Open-label, Multicenter, Multidose, Dose-escalation Study of BMS-936558 (MDX-1106) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms CheckMate-004
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Jul 2017 Planned End Date changed from 1 Oct 2017 to 30 Oct 2018
    • 13 Jul 2017 Planned primary completion date changed from 1 Jan 2017 to 29 Oct 2017.
    • 31 Dec 2016 Results of a retrospective analysis of 3 studies (CA209004, CA209069 and CA209218; n=119) published in the Journal of the National Cancer Institute
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top